Vyome partners with Embryyo to enter AI-enabled medical device market

CAMBRIDGE, Mass. & PUNE, India - Vyome Holdings, Inc. (Nasdaq:HIND) has signed a memorandum of understanding with Embryyo Technologies to jointly pursue opportunities in the global AI-enabled medical device market, according to a press release statement issued Thursday.

The non-binding agreement aims to combine Vyome’s healthcare industry experience with Embryyo’s medical technology capabilities to develop and commercialize smart medical devices for disease management and treatment. The company’s stock has shown positive momentum, with a 4.81% year-to-date return according to InvestingPro data.

"Vyome’s vision is to partner with the smartest talent tackling the biggest healthcare markets along the US-India corridor," said Krishna Gupta, Chairman of Vyome Holdings.

The companies plan to host a global AI-enabled medical device innovation forum for companies operating between the United States and India as part of the partnership.

Embryyo, led by Indian Institutes of Technology alumni, has been operating in the medical technology sector for a decade and is currently developing medical devices in interventional oncology, surgery, wearables, and drug delivery.

"Vyome’s access to global capital markets and the U.S. healthcare ecosystem will accelerate our mission to push the frontiers of medicine," said Nishant Kumar, Co-Founder and CEO of Embryyo Technologies.

Vyome Holdings is a clinical-stage healthcare holding company based in Cambridge, Massachusetts, focusing on immuno-inflammatory conditions. The stock is currently trading near its 52-week high of $14.89, suggesting strong market confidence. Embryyo Technologies specializes in medical device innovation, including need discovery, validation, ideation, and product development. For detailed analysis and additional insights, investors can access the comprehensive Pro Research Report available on InvestingPro.

The memorandum of understanding may be subject to additional conditions, according to the announcement.

In other recent news, Vyome Holdings, Inc. announced an amendment to its Equity Distribution Agreement with Maxim Group LLC, allowing the company to increase its at-the-market public offering of common stock to $12 million, up from the previous limit. Additionally, Vyome Holdings has appointed Kreit & Chiu CPA LLP as its new independent registered public accounting firm, replacing Haskell & White LLP, with no disagreements reported during the transition. Vyome’s Board of Directors is also reviewing strategic alternatives for Livechain Inc., in which the company holds a 70% stake. In a significant development, Vyome completed its merger with ReShape Lifesciences and will begin trading on Nasdaq under the name Vyome Holdings, Inc. and the ticker symbol "HIND." The merger includes a 1-for-4 reverse stock split of ReShape’s common stock. As part of the merger terms, ReShape Lifesciences provided a $200,000 loan to Vyome Therapeutics for various expenses related to the merger agreement. The loan carries an annual interest rate of 8.0% and will be forgiven if the merger completes before September 30, 2025. The newly formed Vyome Holdings will also see a complete overhaul of its Board of Directors, with none of ReShape’s current board members remaining.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.